logo
Plus   Neg
Share
Email

Thermo Fisher Terminates Merger Deal With QIAGEN - Quick Facts

Thermo Fisher Scientific Inc. (TMO) said the company's offer to acquire all of the ordinary shares of QIAGEN N.V. (QGEN) has lapsed as the minimum acceptance threshold condition to the offer has not been satisfied. Thermo Fisher has terminated the acquisition deal with QIAGEN, and QIAGEN will pay to Thermo Fisher an expense reimbursement payment of $95 million in cash.

By the end of the acceptance period on August 10, 2020, a total of 107,546,187 QIAGEN shares, representing 47.02% of the issued and outstanding ordinary shares of QIAGEN, were validly tendered into the offer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
U.S. tech giant Google is laying the groundwork for a fiber-optic network that will connect the first time through Saudi Arabia and Israel, opening a new global internet traffic corridor, the Wall Street Journal reported, citing people familiar with the plans. The link would be established as part of an optical-fiber cable line connecting Europe with India. U.S. retailers Best Buy Co. Inc., Abercrombie & Fitch Co., and Dollar Tree Inc. on Tuesday reported results for the third quarter that surpassed analysts' expectations. The upbeat results indicate that retailers have largely recovered from the impact of the coronavirus pandemic just as the holiday season approaches. The companies have also intensified their focused on digital sales. The U.S. Food and Drug Administration approved the first drug to treat primary hyperoxaluria type 1 (PH1), an ultra-rare genetic disorder which causes recurrent kidney stones and loss of kidney function. Alnylam Pharmaceuticals' Oxlumo (lumasiran) in the form of injection lowers urinary oxalate levels in pediatric and adult patients.
Follow RTT